PRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three- and nine-month periods ended

condensed Consolidated Financial Statements for the three- and nine-month periods ended September 30, 2021, included herein, have been prepared in accordance with International Financial Reporting Standards ( IFRS ) as issued by the

International Accounting Standards Board ( IASB ). The Consolidated Financial Statements are presented in euros. All references in this interim report to $, and U.S. dollars mean U.S. dollars and all references to

and euros mean euros, unless otherwise noted.

This interim report, including Management s Discussion and

Analysis of Financial Condition and Results of Operations, contain statements that constitute forward-looking statements within the meaning of Section 21E of the Exchange Act and Section 27A of the Securities Act of 1933, as amended

(the Securities Act ). All statements other than statements of historical facts, including statements regarding our future results of operations and financial position, business and commercial strategy, potential market opportunities,

products and product candidates, research pipeline, ongoing and planned preclinical studies and clinical trials, regulatory submissions and approvals, research and development costs, timing and likelihood of success, as well as plans and objectives

of management for future operations are forward-looking statements. Many of the forward-looking statements contained in this interim report can be identified by the use of forward-looking words such as anticipate, believe,

could, expect, should, plan, intend, estimate, will and potential, among others. Forward-looking statements are based on our management s beliefs

and assumptions and on information available to our management at the time such statements are made. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the

forward-looking statements due to various factors, including, but not limited to: the severity and duration of the evolving COVID-19 pandemic and the resulting impact on macro-economic conditions; inconclusive

clinical trial results or clinical trials failing to achieve one or more endpoints, early data not being repeated in ongoing or future clinical trials, failures to secure required regulatory approvals, disruptions from failures by third-parties on

whom we rely in connection with our clinical trials, delays or negative determinations by regulatory authorities, changes or increases in oversight and regulation; increased competition; manufacturing delays or problems, inability to achieve

enrollment targets, disagreements with our collaboration partners or failures of collaboration partners to pursue product candidates, legal challenges, including product liability claims or intellectual property disputes, commercialization factors,

including regulatory approval and pricing determinations, disruptions to access to raw materials or starting material, proliferation and continuous evolution of new technologies; disruptions to Immatics business; management changes;

dislocations in the capital markets; and other important factors described under Risk Factors in our Annual Report on Form 20-F/A for the year ended December 31, 2020, filed with the

Securities and Exchange Commission on October 28, 2021 and those described in our other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they were made. Because forward-looking

statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events.

Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not

plan to publicly update or revise any forward-looking statements, whether as a result of any new information, future events, changed circumstances or otherwise.

We own various trademark registrations and applications, and unregistered trademarks, including

Immatics , XPRESIDENT , ACTengine , ACTallo , ACTolog , XCEPTOR ,

TCER , AbsQuant , IMADetect and our corporate logo. All other trade

names, trademarks and service marks of other companies appearing in this interim report are the property of their respective owners. Solely for convenience, the trademarks and trade names in this interim report may be referred to without the and symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the

fullest extent under applicable law, their rights thereto. We do not intend to use or display other companies trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

As used in this interim report, the terms Immatics, we, our, us, the Group and the

Company refer to Immatics N.V. and its subsidiaries, taken as a whole, unless the context otherwise requires. The unaudited condensed consolidated financial statements and Management s Discussion & Analysis of Financial Condition

and Results of Operations in this interim report are related to Immatics N.V. and its German subsidiary Immatics Biotechnologies GmbH as well as its U.S. subsidiary Immatics U.S. Inc.

Unaudited Condensed Consolidated Statement of Financial Position of Immatics N.V.

The accompanying notes are an integral part of these condensed consolidated financial statements.

Unaudited Condensed Consolidated Statement of Loss of Immatics N.V.

The accompanying notes are an integral part of these condensed consolidated financial statements.

Unaudited Condensed Consolidated Statement of Comprehensive Loss of Immatics N.V.

The accompanying notes are an integral part of these condensed consolidated financial statements.

Unaudited Condensed Consolidated Statement of Cash Flows of Immatics N.V.

The accompanying notes are an integral part of these condensed consolidated financial statements.

Unaudited Condensed Consolidated Statement of Changes in Shareholders equity (deficit) of Immatics

The accompanying notes are an integral part of these condensed consolidated financial statements.

Notes to the Unaudited Condensed Consolidated Financial Statements of Immatics N.V.

1. Group information

Immatics N.V, together with its

German subsidiary Immatics Biotechnologies GmbH and its U.S. subsidiary, Immatics US Inc., ( Immatics or the Group ) is a biotechnology group that is primarily engaged in the research and development of T cell redirecting

immunotherapies for the treatment of cancer. Immatics N.V., a Dutch public limited liability company, was converted on July 1, 2020 from Immatics B.V., a Dutch company with limited liability. Immatics Biotechnologies GmbH and Immatics US Inc.

became subsidiaries of Immatics N.V. as part of the ARYA Merger on July 1, 2020. Immatics N.V is registered with the commercial register at the Netherlands Chamber of Commerce under RSIN 861058926 with a corporate seat in Amsterdam and is

located at Paul-Ehrlich Str. 15 in 72076 T bingen, Germany. Prior to July 1, 2020, Immatics N.V. was a shell company with no active trade or business or subsidiaries and all relevant assets and liabilities as well as income and expenses

were borne by Immatics Biotechnologies GmbH and its U.S. subsidiary Immatics US, Inc. Therefore, the comparable financial results for the nine months ended September 30, 2020, include losses, comprehensive losses and cash flows for the six

months ended June 30, 2020 which represent consolidated financial results of Immatics Biotechnologies GmbH.

These interim condensed consolidated

financial statements of the Group for the three and nine months ended September 30, 2021, were authorized for issue by the Audit Committee of Immatics N.V. on November 16, 2021.

2. Significant events and changes in the current reporting period

The Group was affected by the following events or transactions during the three and nine months ended September 30, 2021.

December 2019, a novel strain of coronavirus ( COVID-19 ) emerged. In response, many countries and businesses still institute travel restrictions, quarantines, and office closures. The extent of the

pandemic and governmental responses may impact our ability to obtain raw materials and equipment used for research and development, obtain sufficient additional funds to finance our operations, and conduct clinical trials, any of which could

materially and adversely affect our business.

Management continues to monitor the situation and enacted significant measures to protect the Group s

supply chain, employees, and the execution of clinical trials. To date, the pandemic does not significantly impact the Group. The ongoing spread of COVID-19 may in the future negatively impact the Group s

ability to conduct clinical trials, including potential delays and restrictions on the Group s ability to recruit and retain patients, and the availability of principal investigators and healthcare employees.

COVID-19 could also affect the operations of contract research organizations, which may also result in delays or disruptions in the supply of product candidates. Immatics continues to expand its clinical

programs with additional clinical trial sites opening in the U.S. and in Europe. Given the ongoing vaccination programs both in the U.S. and in Europe we currently do not expect significant negative impacts on the Group s activities in the

future. However, COVID-19 also showed the ability of mutation with potential mutants in the future limiting the impact of the vaccines. This could again lead to further negative impacts.

3.1 Significant accounting policies

The interim condensed consolidated financial statements of the Group as of September 30, 2021 and for the three and nine months

ended September 30, 2021 and 2020 have been prepared in accordance with International Accounting Standard 34 ( Interim Financial Reporting ), as issued by the International Accounting Standards Board ( IASB ).

The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements and

should be read in conjunction with the Group s annual financial statements for the year ended December 31, 2020, which have been prepared in accordance with International Financial Reporting Standards ( IFRS ) as issued by the

IASB, taking into account the recommendations of the International Financial Reporting Standards Interpretations Committee ( IFRS IC ).

The interim condensed consolidated financial statements are presented in Euros. Amounts are stated in

thousands of Euros, unless otherwise indicated.

The accounting policies adopted in the preparation of the interim condensed consolidated financial

statements are consistent with those followed in the preparation of the Group s annual consolidated financial statements for the year ended December 31, 2020. The new and amended standards and interpretations applied for the first time as

of January 1, 2021, as disclosed in the notes to the consolidated financial statements for the year ended December 31, 2020, had no impact on the interim condensed consolidated financial statements of the Group for the three and nine

months ended as of September 30, 2021.

As of September 30, 2021, Immatics holds bonds. The bonds` contractual cash flows represent solely

payments of principal and interest and Immatics intends to hold the bonds to collect the contractual cash flows. The Group therefore accounts for the bonds as a financial asset at amortized cost.

The Group had a non-controlling interest, representing approximately 3.96% of the Group s Immatics US, Inc.

subsidiary as of June 30, 2020, held by MD Anderson. On July 1, 2020 and as part of the ARYA Merger, this non-controlling interest in Immatics US, Inc. was exchanged for ordinary shares in Immatics

3.2 Restatement of prior period Unaudited Condensed Consolidated Financial Statements to correct the presentation of the warrants

On April 12, 2021, the Acting Director of the Division of Corporation Finance and Acting Chief Accountant of the Securities and Exchange Commission (the

SEC ) together issued a statement regarding the accounting and reporting considerations for warrants issued by special purpose acquisition companies entitled Staff Statement on Accounting and Reporting Considerations for Warrants

Issued by Special Purpose Acquisition Companies ( SPACs ) (the SEC Statement ). The SEC Statement clarified guidance for all SPAC-related companies regarding the accounting and reporting for their warrants that could

result in the warrants issued by SPACs being classified as a liability measured at fair value, with non-cash fair value adjustments recorded in the statement of operations for each reporting period. This

guidance was applicable for companies that reported using U.S. GAAP.

Under IFRS, there are alternative perspectives on whether warrants issued by a SPAC

that are considered in determining the IFRS 2 charge for listing services can (i) continue to be accounted for under IFRS 2 and presented in equity or (ii) should be evaluated under IAS 32 and presented as a liability and adjusted to fair

value at the balance sheet date.

Given the alternative perspectives, Immatics believed there was a choice to account for the warrants under IFRS 2 as

part of equity or as a liability under IAS 32 and, in its previously published financial statements, elected to present the warrants as part of equity. However, Immatics has observed that another foreign private issuer has restated its financial

statements recently following the dialogue it reported with the Staff, and changed the presentation of its warrants from equity to liability under IFRS.

The Company reviewed and discussed the accounting treatment of its warrants and concluded that, in light of the recent developments, it should restate its

financial statements to correct for the misapplication of IFRS and to account for the warrants as a liability that is adjusted to fair value and therefore filed the Amendment No.1 on form 20-F for the year

ended December 31, 2020 on October 28, 2021 to restate the financial statements of 2020. The Company also filed a separate Amendment No.1 on form 6-K to restate the interim financial statements for

the three-month period ended March 31, 2021 and separately to restate the interim financial statements for the three and six-month period ended June 30, 2021. Consequently, within these financial

statements Immatics has restated its unaudited Condensed Consolidated Statement of Loss for the three-months ended and nine-months ended September 30, 2020, its unaudited Condensed Consolidated Statement of Comprehensive Loss for the

three-months ended and nine-months ended September 30, 2020 and its unaudited interim Condensed Consolidated Statement of Cash Flows for nine-months ended September 30, 2020.

The following represents the reconciliation of our unaudited Condensed Consolidated Statement of Loss for